Questions Raised by a Genetic Test Report
"Homozygous deletion of exon 7 in the SMN1 gene indicates carrier status for Spinal Muscular Atrophy." When one or both partners in a couple planning pregnancy receive such a genetic test report, an urgent question arises: Can IVF technology be used to select embryos that do not carry the disease-causing gene, thereby having a healthy child?
The answer is: Yes. This technology is called PGT-M (Preimplantation Genetic Testing for Monogenic Disorders), a key component of third-generation IVF technology. Currently, reproductive centers in China with PGT qualifications can perform PGT-M testing for SMA.
Spinal Muscular Atrophy and PGT-M: Direct Answers
Spinal Muscular Atrophy (SMA) is an autosomal recessive genetic disorder primarily caused by mutations in the SMN1 gene. If both partners are SMA carriers, there is a 25% chance their offspring will be affected, a 50% chance of being a carrier, and a 25% chance of being completely unaffected.
Through the PGT-M technology of third-generation IVF, embryos can be genetically tested before implantation into the uterus, allowing for the selection of unaffected embryos for transfer. This means SMA can be screened for via third-generation IVF technology in China.
Why PGT-M is Needed: Genetic Mechanism and Reproductive Risk
The inheritance pattern of SMA determines its reproductive risk. When both partners are SMA carriers, each natural pregnancy has a 1 in 4 chance of resulting in an affected child. For families who have already had a child with SMA, the risk of having another affected child is also 1 in 4.
The core value of PGT-M lies in identifying embryos carrying the disease-causing gene at the embryonic stage, thereby avoiding pregnancy termination or the birth of an affected child due to transferring an affected embryo.
Carrier Frequency and Population Risk
The carrier rate for SMA in the general population is approximately 1 in 40 to 1 in 50, making it a relatively common single-gene disorder. This means that without any screening, the risk of having a child with SMA is a real possibility.
Doctor's Perspective: Medical Decision-Making for PGT-M
From the perspective of reproductive medicine and genetic counseling, doctors focus on several key aspects when determining suitability for PGT-M:
1. Confirmation of Genetic Diagnosis
A prerequisite for PGT-M is that both partners must have completed genetic diagnosis to identify their specific disease-causing gene mutations. For SMA, approximately 95% of cases are caused by a homozygous deletion of exon 7 in the SMN1 gene, with the remainder caused by other types of mutations.
2. Necessity of Genetic Counseling
Genetic counseling is an essential step before entering the PGT-M process. Genetic counselors will assess the inheritance pattern, testing strategy, accuracy of embryo testing, and residual risks, and explain the limitations of testing and potential unexpected findings.
3. Consideration of Embryo Quantity
PGT-M requires a biopsy of the embryo. It is generally recommended to have a sufficient number of embryos (usually at least 3-5 blastocysts) for testing to increase the probability of obtaining a transferable embryo. Women with diminished ovarian reserve or advanced age may need a more cautious assessment of expected egg yield.
Easily Overlooked Details
In the PGT-M process for SMA, several key details are often overlooked:
Both partners must complete genetic testing
Testing only one partner is insufficient for PGT-M. A genetic testing strategy can only be designed when the genotypes of both partners are known. Some people mistakenly believe that "only one partner has a family history, so the other doesn't need testing."
Timeliness of Test Results
Genetic test results are valid long-term, but it is recommended to have genetic counseling within 6 months before starting the IVF cycle to ensure the testing strategy and plan are aligned with current technology.
Timing of Embryo Biopsy
PGT-M typically uses blastocyst-stage biopsy, where the embryo is cultured for 5-6 days, and 3-5 cells are removed from the trophectoderm for testing. The biopsy itself has some impact on the embryo's continued development and implantation ability, but the overall risk is manageable.
Final Confirmation via Prenatal Diagnosis
PGT-M technology cannot guarantee 100% that an embryo is completely normal. After transfer, prenatal diagnosis (such as amniocentesis) during pregnancy is still recommended for final confirmation.
Common Pitfalls
In reality, PGT-M can only detect known disease-causing gene mutations. If the patient's specific mutation type is not clearly identified, or if there are mutation types that the testing technology cannot cover, the feasibility of PGT-M may be affected.
Embryo genetic testing has a certain technical error rate, including allele dropout (ADO), chromosomal mosaicism, and sample contamination, which can lead to inaccurate results. Currently, the accuracy of PGT-M ranges from 95% to 99%, depending on the testing platform and mutation type.
Not necessarily. The indication for PGT-M is when both partners are SMA carriers, or one partner is affected and the other is a carrier. If only one partner is a carrier, the risk to offspring is extremely low (risk only exists if the partner is also a carrier), and PGT-M is generally not recommended.
Embryo biopsy may have some impact on the embryo, but studies show that the rates of continued blastocyst development, implantation, and live birth after biopsy are not significantly different from those of non-biopsied embryos. PGT-M has been performed in hundreds of thousands of cycles globally, and the safety of the technology has been widely validated.
Actual Process: From Genetic Diagnosis to Embryo Transfer
The PGT-M process for SMA can be divided into the following stages:
Stage 1: Genetic Diagnosis and Genetic Counseling
- Both partners undergo SMN1 gene testing to identify mutation sites
- A genetic counselor assesses the inheritance pattern and confirms PGT-M indication
- A personalized testing plan is developed, including selection of testing platform, probe design, etc.
Stage 2: Standard IVF Process
- Ovarian stimulation for the woman (approximately 10-14 days)
- Ultrasound monitoring of follicle development
- Egg retrieval surgery (minimally invasive, under intravenous sedation)
- In vitro fertilization (ICSI or conventional IVF)
- Embryo culture to the blastocyst stage (5-6 days)
Stage 3: Embryo Biopsy and Genetic Testing
- Blastocyst grading, selection of good-quality blastocysts for biopsy
- Trophectoderm biopsy (3-5 cells)
- Whole genome amplification (WGA)
- Genetic testing (PCR or NGS platform)
- Result interpretation and selection of transferable embryos
Stage 4: Embryo Transfer and Subsequent Confirmation
- Selection of transferable embryos (normal embryos or carrier embryos)
- Frozen or fresh embryo transfer
- Pregnancy test 12-14 days after transfer
- Prenatal diagnosis during pregnancy for confirmation (amniocentesis)
Timeline: How Long Does the Entire Cycle Take?
From initiating genetic diagnosis to the final transfer, it typically takes 3-6 months. The specific time allocation is as follows:
| Stage | Time | Notes |
|---|---|---|
| Genetic Diagnosis & Genetic Counseling | 2-4 weeks | Depends on testing method and hospital scheduling |
| Ovarian Stimulation & Egg Retrieval | 2-3 weeks | Starting from the menstrual cycle |
| Embryo Culture & Biopsy | 1-2 weeks | Culture to blastocyst stage |
| Genetic Testing | 4-6 weeks | Whole genome amplification and gene testing |
| Result Analysis & Transfer Preparation | 1-2 weeks | Genetic counseling to confirm results |
| Embryo Transfer | 1 day | Frozen or fresh embryo transfer |
If using frozen-thawed embryo transfer, the entire cycle can be arranged flexibly and does not need to be continuous.
Frequently Asked Questions
Observations from Practitioners
In genetic counseling clinics, several common phenomena regarding SMA and PGT-M are worth noting:
More and more people planning pregnancy are proactively undergoing SMA carrier screening before or during early pregnancy. For couples who have been identified as carriers, PGT-M is an effective means of preventing the transmission of SMA.
Some couples have overly high expectations of PGT-M, believing that "having PGT-M guarantees a 100% healthy baby." In reality, PGT-M can only test for specific gene mutations and cannot detect all genetic diseases. Additionally, the inherent risks of embryo development failure (e.g., embryo arrest, implantation failure) objectively exist.
PGT-M is not a simple "blood test - testing - transfer" process; genetic counseling runs throughout the entire cycle. From the initial genetic diagnosis strategy, to the design of the embryo testing plan, to result interpretation and transfer decisions, the involvement of a genetic counselor directly impacts the effectiveness and safety of the testing.
Reproductive centers in China with PGT qualifications vary in terms of testing platforms, laboratory experience, and genetic counseling team composition. Choosing a center with experience in single-gene disorder testing and a well-established genetic counseling system is an important factor for a successful PGT-M process.
When is PGT-M for SMA Suitable?
- Both partners are SMA carriers (confirmed by genetic testing)
- One partner is affected by SMA, and the other is a carrier
- Have previously had a child with SMA and wish to avoid having another affected child
- Have a family history of SMA, and both partners have been confirmed as carriers
When is it Not Suitable?
- Only one partner is an SMA carrier, and the other partner has been tested and confirmed not to be a carrier
- The type of disease-causing gene mutation has not been clearly identified
- The woman has severely diminished ovarian reserve, with a very low expected egg yield (e.g., AMH < 0.5 ng/mL)
- There are contraindications to IVF (e.g., severe uterine abnormalities, uncontrolled systemic diseases, etc.)
Risk Reminder
PGT-M is a mature technology, but it is not without limitations and risks: embryo test results may have false positives or false negatives; some embryos may be unsuitable for transfer due to abnormal test results; the biopsy process may affect the embryo's continued development; the testing cycle may require multiple menstrual cycles; even after transferring a normal embryo, there is still a possibility of early miscarriage or other obstetric complications.
Before deciding to undergo PGT-M, it is recommended to have thorough discussions with a genetic counselor and reproductive specialist to understand the specific risks and success expectations for your individual situation.
Comments (0)